Effect of renal impairment on atherosclerosis: Only partially mediated by homocysteine

Nephrology Dialysis Transplantation

Volumn 31, Issue 6, 2016, Pages 937-944

  Spence, J David ^a   Urquhart, Bradley L ^b   Bang, Heejung ^c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

TMAO

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; YOUNG ADULT; ATHEROSCLEROSIS; BLOOD; CAROTID STENOSIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

ATHEROSCLEROSIS; BIOMARKERS; CAROTID STENOSIS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84975167803     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv380     Document Type: Article

References (60)

1. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
3. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007; 7: 830-838
4. Spence JD, Cordy P, Kortas C et al. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. Am J Nephrol 1999; 18: 405-410
5. Rodionov RN, Lentz SR. The homocysteine paradox. Arterioscler Thromb Vasc Biol 2008; 28: 1031-1033
6. Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA 2011; 306: 2610-2611
7. Spence JD. B vitamin therapy for homocysteine: renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med 2013; 51: 633-637
8. Huang T, Chen Y, Yang B et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 2012; 31: 448-454
9. Ji Y, Tan S, Xu Y et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis. Neurology 2013; 81: 1298-1307
10. Huo Y, Li J, Qin X et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015; 313: 1325-1335
11. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: e188-e189
12. Al Shali K, House AA, Hanley AJ et al. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005; 178: 319-325
13. Klein JH, Hegele RA, Hackam DG et al. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008; 28: 1851-1856
14. Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012; 32: 1550-1551
15. Koppe L, Klich A, Dubourg L et al. Performance of creatinine-based equations compared in older patients. J Nephrol 2013; 26: 716-723
16. Spence JD, Eliasziw M, DiCicco M et al. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 2002; 33: 2916-2922
17. Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep 2009; 11: 21-27
18. Mathiesen EB, Johnsen SH, Wilsgaard T et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromso Study. Stroke 2011; 42: 972-978
19. Barnett HJM, Taylor DW, Eliasziw M et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe carotid stenosis. N Engl J Med 1998; 339: 1415-1425
20. Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol 1982; 13: 290-312
21. MacKinnon DP, Dwyer JH. Estimating mediated effects in prevention studies. Eval Rev 1993; 17: 144-158
22. Robertson J, Iemolo F, Stabler SP et al. Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005; 172: 1569-1573
23. Spence JD. Mechanisms of thrombogenesis in atrial fibrillation. Lancet 2009; 373: 1006
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988
25. Poli D, Antonucci E, Cecchi E et al. Culprit factors for the failure of wellconducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005; 36: 2159-2163
26. Boger RH, Bode-Boger SM, Sydow K et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557-1564
27. Rodionov RN, Dayoub H, Lynch CM et al. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res 2010; 106: 551-558
28. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3: 1646-1654
29. Boger RH, Lentz SR, Bode-Boger SM et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100: 161-167
30. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 2012; 59: 375-381
31. Potter K, Hankey GJ, Green DJ et al. Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 2008; 28: 1158-1164
32. House AA, Eliasziw M, Cattran DC et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010; 303: 1603-1609
33. Spence JD, Eliasziw M, House AA. B-Vitamin therapy for diabetic nephropathy: reply. JAMA 2010; 304: 636-637
34. Koyama K, Yoshida A, Takeda A et al. Abnormal cyanide metabolism in uraemic patients. Nephrol Dial Transplant 1997; 12: 1622-1628
35. Koyama K, Ito A, Yamamoto J et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010; 55: 1069-1078
36. Loland KH, Bleie O, BorgeraasHet al. The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. PLoS One 2013; 8: e64774
37. Freeman AG. Hydroxocobalamin versus cyanocobalamin. J R Soc Med 1996; 89: 659
38. Wang R. Is H2S a stinky remedy for atherosclerosis? Arterioscler Thromb Vasc Biol 2009; 29: 156-157
39. Perna AF, Ingrosso D. Low hydrogen sulphide and chronic kidney disease: a dangerous liaison. Nephrol Dial Transplant 2012; 27: 486-493
40. Exner M, Hermann M, Hofbauer R et al. Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Free Radic Biol Med 2004; 37: 146-155
41. Rader DJ, Ischiropoulos H. 'Multipurpose oxidase' in atherogenesis. Nat Med 2007; 13: 1146-1147
42. Spence JD. Effects of the intestinal microbiome on constituents of red meat and egg yolks: a newwindow opens on nutrition and cardiovascular disease. Can J Cardiol 2014; 30: 150-151
43. Simenhoff ML, Burke JF, Saukkonen JJ et al. Biochemical profile or uremic breath. N Engl J Med 1977; 297: 132-135
44. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63
45. Koeth RA, Wang Z, Levison BS et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-585
46. Tang WHW,Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-1584
47. Tang WH,Wang Z, Kennedy DJ et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116: 448-455
48. Moraes C, Fouque D, Amaral AC et al. Trimethylamine N-oxide from gut microbiota in chronic kidney disease patients: focus on diet. J Ren Nutr 2015; 25: 459-465
49. Johri AM, Heyland DK, Hetu MF et al. Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies. Nutr Metab Cardiovasc Dis 2014; 24: 808-814
50. Poesen R, Viaene L, Verbeke K et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J AmSoc Nephrol 2013; 8: 1508-1514
51. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558
52. Dou L, Jourde-Chiche N, Faure V et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5: 1302-1308
53. Dou L, Sallee M, Cerini C et al. The cardiovascular effect of the uremic solute indole-3 acetic Acid. J Am Soc Nephrol 2015; 26: 876-887
54. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
55. Liabeuf S, Barreto DV, Barreto FC et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
56. Wu IW, Hsu KH, Hsu HJ et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients- A prospective cohort study. Nephrol Dial Transplant 2012; 27: 1169-1175
57. Schulman G, Agarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577
58. Urquhart BL, Freeman DJ, Spence JD et al. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 2007; 49: 109-117
59. Nesrallah G, Suri R, Moist L et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 2003; 42 (1 Suppl): 13-17
60. Schulman G, Berl T, Beck GJ et al. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol 2015; 26: 1732-1746